MAP2K7 and melanoma: Among melanoma patients who had previously been treated with and progressed on BRAF and/or MEK inhibitors, 3 of 19 patients (15%) achieved a PR (including a durable response in one patient that remained on study for over 38 months), 6 patients had stable disease, and 10 patients had progressive disease.